Tudor Investment Corp
ENTA icon

Tudor Investment Corp’s Enanta Pharmaceuticals ENTA Stock Holding History

Tudor Investment Corp’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$131K Buy
+10,381
New +$139K ﹤0.01% 3439
2025
Q4 		– Sell
-10,443
Closed -$125K – 3628
2025
Q3 		$125K Buy
+10,443
New +$83.5K ﹤0.01% 3249
2025
Q2 		– Sell
-10,347
Closed -$57.1K – 3380
2025
Q1 		$57.1K Hold
10,347
– – ﹤0.01% 2954
2024
Q4 		$59.5K Sell
10,347
-2
-0% -$19 ﹤0.01% 2925
2024
Q3 		$107K Buy
+10,349
New +$135K ﹤0.01% 2590
2024
Q2 		– Sell
-10,405
Closed -$182K – 2440
2024
Q1 		$182K Buy
+10,405
New +$138K ﹤0.01% 2054
2023
Q3 		– Sell
-10,365
Closed -$222K – 2433
2023
Q2 		$222K Buy
+10,365
New +$306K ﹤0.01% 2169
2022
Q4 		– Sell
-10,327
Closed -$536K – 2508
2022
Q3 		$536K Sell
10,327
-1,659
-14% -$96.9K 0.01% 1344
2022
Q2 		$567K Sell
11,986
-17,268
-59% -$937K 0.01% 1213
2022
Q1 		$2.08M Buy
29,254
+2,308
+9% +$150K 0.05% 534
2021
Q4 		$2.02M Buy
26,946
+19,049
+241% +$1.49M 0.03% 619
2021
Q3 		$449K Sell
7,897
-43,479
-85% -$2.15M 0.01% 1731
2021
Q2 		$2.26M Buy
51,376
+31,365
+157% +$1.54M 0.04% 512
2021
Q1 		$987K Sell
20,011
-24,075
-55% -$1.2M 0.02% 841
2020
Q4 		$1.86M Buy
+44,086
New +$1.94M 0.05% 446
2020
Q3 		– Sell
-11,227
Closed -$564K – 1357
2020
Q2 		$564K Buy
+11,227
New +$581K 0.03% 679
2017
Q3 		– Sell
-5,802
Closed -$209K – 1127
2017
Q2 		$209K Sell
5,802
-6,100
-51% -$195K 0.01% 873
2017
Q1 		$367K Sell
11,902
-3,568
-23% -$111K 0.01% 874
2016
Q4 		$518K Buy
+15,470
New +$443K 0.01% 703
2015
Q2 		– Sell
-9,800
Closed -$300K – 1533
2015
Q1 		$300K Buy
9,800
+813
+9% +$31.6K 0.01% 1049
2014
Q4 		$457K Sell
8,987
-11,609
-56% -$520K 0.02% 788
2014
Q3 		$815K Buy
+20,596
New +$821K 0.03% 385

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SSC
Spruce Street Capital New York $416M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Tudor Investment Corp's ENTA Position: Q1 2026 in Review

Tudor Investment Corp opened a new position in Enanta Pharmaceuticals (ENTA) in Q1 2026: 10,381 shares worth $131K. The stake represents ﹤0.01% of the portfolio and ranks #3439 among its holdings. This is a return to the name: Tudor Investment Corp previously reported a position in ENTA as recently as Q3 2025.

Tudor Investment Corp first reported a position in ENTA in Q3 2014 and has held it in 22 quarters since. The position peaked at $2.26M in Q2 2021. 133 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

  • Tudor Investment Corp held 10,381 shares of Enanta Pharmaceuticals worth $131K as of Q1 2026.
  • Enanta Pharmaceuticals was a new Tudor Investment Corp position in Q1 2026.
  • Enanta Pharmaceuticals made up ﹤0.01% of Tudor Investment Corp's portfolio in Q1 2026, its #3439 holding.
  • Tudor Investment Corp first reported a position in Enanta Pharmaceuticals in Q3 2014 and has held it in 22 quarters since.
  • Tudor Investment Corp's Enanta Pharmaceuticals position peaked at $2.26M in Q2 2021.
  • 133 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on Tudor Investment Corp's 13F filing for Q1 2026, filed 15 May 2026.